

Interface and Formulary Update - Issue 31 – June and July 2024

Key messages from June and July 2024 TAG meetings (ratified by Medicines Optimisation Programme Board)

<p>Commissioning Review –</p> <ul style="list-style-type: none"> • Sodium Valproate • Valproic Acid • Valproate Semisodium <p>These classifications only apply to women of childbearing potential (under 55).</p> <p>Other patient groups will be reviewed in due course.</p>	<ul style="list-style-type: none"> • Epilepsy and bipolar <ul style="list-style-type: none"> ○ ADVICE – Specialist Initiation only until stable, then transfer to primary care ○ Red Hospital Only - women childbearing potential where PREVENT not met ○ Double Red for use in pregnancy. There may be some patients where it is appropriate to continue, but they will remain under specialist care. • Migraine – <ul style="list-style-type: none"> ○ BLACK – Not commissioned for patients under 55 ○ ADVICE – Secondary care to initiate for those over 55 • All other indications - BLACK – Not commissioned
<p>Commissioning Review - Daridorexant for treating long-term insomnia as per TA922</p>	<ul style="list-style-type: none"> • Daridorexant to be made available only after patient has used one of the sleep apps available as part of CBTi • GREEN - Drugs that can be initiated by prescriber in primary care
<p>Commissioning Review - Doxylamine/Pyridoxine for treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management</p>	<ul style="list-style-type: none"> • ADVICE – Initiate in hospital and then continue in primary care once patient is stable and treatment has been proven to be effective • Not to be initiated in primary care
<p>Commissioning Review - Tirzepatide for weight management</p>	<ul style="list-style-type: none"> • BLACK – not commissioned. Not for prescribing in primary or secondary care • Medicines Optimisation team have published a commissioning bulletin to support with requests. • There is a requirement to find a way to support this patient group
<p>Commissioning Review - Ergocalciferol / Vitamin D Injections – use in primary care</p>	<ul style="list-style-type: none"> • ADVICE – GP can prescribe at specialist request • NHS patients can access in primary care without repatriation to local Trust • This classification will not cover patients transferring from private providers – work ongoing regarding management of this cohort.
<p>Commissioning Review and Pathway – Migraine prevention and treatment</p>	<ul style="list-style-type: none"> • ADVICE - specialist will initiate and provide the first 12 weeks of medication to the patient – Rimegepant and Atogepant for prevention of migraine • GREEN - Drugs that can be initiated by Prescriber in Primary Care - Rimegepant treatment of migraine • Pathway supported by the TAG
<p>Clinical policy: Puberty suppressing hormones</p>	<ul style="list-style-type: none"> • Regulations introduced to restrict prescribing and supply of puberty suppressing hormones as per NHS England. • Patients under 18 on these medicines have been identified and Prescribing Leads have been contacted with requests to review.

Shared Care Updates

Stimulants for Attention Deficit Hyperactivity Disorder (ADHD) in Children & Young People aged at least 6 years old

Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Children & Young People aged at least 6 years old

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

Hospital	Weekly adalimumab for treatment of psoriasis
	Remdesivir (Veklury®) for treating COVID-19
	Pembrolizumab (Keytruda®) for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over
	Selinexor (Nexpovio®) with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
	Selinexor (Nexpovio®) with bortezomib and dexamethasone for previously treated multiple myeloma (replaces TA700)
	Tisagenlecleucel (Kymriah®) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under
	Cladribine (Mavenclad®) for treating relapsing–remitting multiple sclerosis (replaces TA493)
	Alemtuzumab (Lemtrada®) for treating highly active relapsing–remitting multiple sclerosis
	Natalizumab (Tysabri®) for the treatment of adults with highly active relapsing–remitting multiple sclerosis
	Dabrafenib (Finlee®) with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over
	Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome
	Modified-release Budesonide (Kinpeygo®) for treating primary IgA nephropathy
	Deucravacitinib for treating moderate to severe plaque psoriasis
	Ivosidenib (Tibsovo®) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
	Voxelotor (Oxbryta®) for treating haemolytic anaemia caused by sickle cell disease
Tafamidis (Vyndaqel®) for treating transthyretin amyloidosis with cardiomyopathy	
BLACK	Pembrolizumab (Keytruda®) for treating relapsed or refractory classical Hodgkin lymphoma (partially replaced by TA967)
	Tixagevimab plus Cilgavimab for treating COVID-19
	Pembrolizumab with Gemcitabine and Cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
	Melphalan Flufenamide with Dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
	Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)
	Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)
	Trastuzumab Deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
	Zanubrutinib with Obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
	Pembrolizumab (Keytruda®) with Trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
	Nivolumab (Opdivo®) for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over
Baricitinib (Olumiant®) for treating juvenile idiopathic arthritis in people 2 years and over	

Formulary and Guidance Updates

- **Asthma Resources**
 - Asthma Primary Care Guidelines Norfolk and Waveney V2.1 update May 2024
 - Maintenance and Reliever Therapy Norfolk and Waveney Guidance
 - Norfolk and Waveney Primary Care Best Value Inhalers for ASTHMA
- Norfolk and Waveney **suggested options to reduce the carbon footprint of inhalers** PHASE ONE
Age ≥ 18 years only
- Guideline for the **Treatment of Attention Deficit Hyperactivity Disorder (ADHD)** in Children & Young People (CYP)
- **Hypromellose** 0.3% Preservative Free Eye Drops
 - Evolve discontinued
 - AddTear® added as the best value product of choice
- **Fezolinetant** for vasomotor symptoms associated with the menopause
 - Awaiting publication of NICE guidance. Until then, this remains non-formulary and should not be prescribed. Further information can be found on [Netformulary](#) and [KNoW](#)

Useful Information

Next TAG meeting	Wednesday 4th September 2024
Deadline for agenda submissions	Tuesday 27th August 2024
Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – Medicines Optimisation Home Page	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)

- Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates
- If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net